|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0120 AUD | 0.00% |
|
0.00% | -20.00% |
| 05-27 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 4.29M | - | - | - | - | - |
| 48.41B | |||||
| 34.99B | |||||
| 11.62B | |||||
| 11.47B | |||||
| 8.99B |
- Stock Market
- Stocks
- ACR Stock
- Charts Acrux Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
